Coeliac disease: diagnosis, gluten-free diet, and long-term monitoring in AU

Coeliac disease — common, under-diagnosed, and entirely diet-treatable

Coeliac disease is a lifelong immune-mediated small-bowel condition triggered by gluten — a protein found in wheat, barley, and rye — in people who carry the HLA-DQ2 or DQ8 genetic variants. When gluten is ingested, an abnormal immune response damages the small intestinal lining, causing villous atrophy, impaired absorption, and a systemic autoimmune process that extends well beyond the gut.

Coeliac Australia estimates prevalence at approximately 1 in 70 Australians — and around 80% remain undiagnosed. Women are affected at roughly twice the rate of men, and the condition can present at any age, from infancy through late adulthood.

The condition is associated with other autoimmune conditions: type 1 diabetes (~5–8% prevalence), autoimmune thyroid disease, IgA deficiency, Sjögren’s syndrome, and Down, Turner, and Williams syndromes carry higher background coeliac rates. First-degree relatives have approximately a 10% chance of being affected.

The GP role spans case-finding in people with appropriate risk factors, coordinating the diagnostic pathway, initiating nutritional management, monitoring for complications, and ensuring long-term surveillance.

A. Core clinical — the AU general-practice framework

Who to test

eTG Gastrointestinal and Coeliac Australia recommend testing in patients with:

• Classic GI symptoms: chronic diarrhoea, bloating, abdominal pain, weight loss, steatorrhoea
• Iron deficiency anaemia not responding to supplementation or without an identified cause
• Osteoporosis, especially in younger patients or without clear risk factors
• Unexplained infertility or recurrent miscarriage
• Fatigue, peripheral neuropathy, or cerebellar ataxia without other explanation
• Dermatitis herpetiformis (itchy vesicular blistering rash, extensor surfaces — granular IgA on skin biopsy)
• Elevated liver enzymes without other explanation (autoimmune hepatitis association)
• First-degree relative with confirmed coeliac disease
• Conditions with elevated background prevalence: type 1 diabetes, autoimmune thyroid disease, Down/Turner/Williams syndrome

The gluten-challenge requirement

The single most important and most missed requirement: the patient must be eating gluten at the time of testing — a minimum of 4 slices of wheat bread per day (or equivalent) for at least 6 weeks before serology. A patient already on a self-initiated gluten-free diet will have false-negative serology and false-negative biopsy. This must be explained clearly before arranging tests.

Diagnostic investigations

Per Coeliac Australia testing guidelines and eTG:

First-line serology (while eating gluten):

• Anti-tTG IgA — high sensitivity and specificity; primary screening test
• Total IgA — approximately 3% of the general population and a higher proportion of those with coeliac disease are IgA-deficient; if deficient, use anti-tTG IgG, anti-DGP IgG, or anti-EMA IgG instead
• FBC, iron studies, B12, folate, vitamin D, calcium, TSH, LFTs, HbA1c — screens for associated deficiencies and autoimmune comorbidities

Confirmation:

• Duodenal biopsy via gastroscopy — gold standard for most Australian adults; Marsh 3a/b/c villous atrophy plus increased intraepithelial lymphocytes and crypt hyperplasia confirms the diagnosis
• HLA-DQ2/DQ8 genotyping — once per lifetime; useful when: diagnosis is equivocal, patient is already on a gluten-free diet before testing, screening first-degree relatives, or to definitively reassure a negative result (negative HLA virtually excludes coeliac disease)

Emerging no-biopsy approach: Paediatric gastroenterologists in Australia increasingly use a no-biopsy pathway when anti-tTG IgA is ≥10× the upper limit of normal plus positive anti-EMA plus positive HLA plus compatible symptoms (per ESPGHAN criteria). For adults, the 2025 European Society for Coeliac Disease (ESsCD 2025 guideline) conditionally recommends no-biopsy in adults under 45 with anti-tTG IgA ≥10× ULN confirmed in a second sample. This is not yet standard in Australia pending laboratory reference interval harmonisation — duodenal biopsy remains preferred for most Australian adults.

B. Complications and associated conditions

Bone disease

Calcium and vitamin D malabsorption from villous atrophy drives bone loss, often accrued silently over years before diagnosis. Healthy Bones Australia and the RACGP 2024 osteoporosis guideline position coeliac disease as a recognised secondary cause of osteoporosis.

DXA bone densitometry (Medicare-rebatable for coeliac disease) should be performed at diagnosis. Repeat scanning at 2-year intervals until stable on the gluten-free diet, then 5-yearly. Calcium 1000–1300 mg/day from dietary sources; vitamin D 1000–2000 IU daily if deficient. Bisphosphonate per RACGP/Healthy Bones Australia criteria when T-score indicates treatment.

Haematological complications

Iron deficiency anaemia is the most common presentation of coeliac disease in Australian adults, often preceding GI symptoms by years. Folate and B12 deficiency occur from impaired absorption in the proximal small bowel. IV iron (ferric carboxymaltose or iron sucrose, PBS Authority) is preferred when oral iron is poorly tolerated or ineffective with ongoing malabsorption.

Functional hyposplenism

Coeliac disease causes functional splenic hypofunction — the spleen is present but does not filter encapsulated bacteria effectively. This creates susceptibility to serious infections by Streptococcus pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis, similar to asplenia.

Pneumococcal vaccination is essential. Under the National Immunisation Program for medical risk groups, coeliac disease qualifies for free Prevenar 20 (single dose for adults). Annual influenza, COVID per ATAGI, and Shingrix (age-appropriate) are also recommended.

Cancer risk

Untreated or refractory coeliac disease carries a modestly increased risk of enteropathy-associated T-cell lymphoma (EATL). This rare complication typically presents in people with refractory coeliac disease (persistent villous atrophy despite strict gluten-free diet for ≥12 months). Alarm features — weight loss, severe abdominal pain, fevers, night sweats in a known coeliac patient — warrant urgent specialist review.

C. Gluten-free diet — the treatment and its practicalities

The strict, lifelong, gluten-free diet is the only proven treatment for coeliac disease, endorsed by eTG, Coeliac Australia, and GESA. There are no approved pharmacological substitutes. Supplements marketed as “gluten-degrading enzymes” do not provide adequate protection and should not be used as a substitute for dietary vigilance.

Eliminated: wheat (including spelt, kamut, semolina, durum), barley (including malt and beer), rye, and triticale. Oats are tolerated by most people with coeliac disease when uncontaminated, but cross-contamination with wheat is common in Australian supply chains — introduce under dietitian guidance with symptom and serology monitoring.

Cross-contamination prevention: separate toasters, chopping boards, colanders, spreads, and cooking oils. Thoroughly clean shared cookware. Dedicated gluten-free labelled preparation areas when possible.

Coeliac Australia Crossed Grain Trademark certifies products to a fewer than 20 parts per million standard — recommended for high-confidence product selection.

Dietitian support: refer to a Coeliac Australia–accredited dietitian via GPCCMP. Annual dietitian review is recommended, as the gluten-free diet is complex, nutritionally incomplete without planning, and has significant social and economic burden.

D. Australian operations

MBS items for coeliac disease management:

Standard GP consultations (items 23, 36, 44). GP Chronic Condition Management Plan (GPCCMP — items 965/967) qualifies coeliac disease; enables referral to an accredited dietitian, and psychologist via Better Access for adjustment to the dietary diagnosis. 45-to-49-year-old health assessments (item 701), ATSI health assessments (item 715), and 75+ assessments (item 705) all provide opportunities for case-finding.

Serology (anti-tTG IgA plus total IgA — item 71163 range) and confirmatory gastroscopy with duodenal biopsy (item 30473 range) are Medicare-rebatable. HLA-DQ2/DQ8 genotyping (item 73329 range) is once-per-lifetime rebatable. DXA (item 12306) is specifically rebatable for coeliac disease under Medicare.

PBS: Gluten-free food is not PBS-subsidised (DVA and NDIS may cover some exceptions). Parenteral iron preparations (ferric carboxymaltose, iron sucrose, iron polymaltose) are PBS Authority Required. Bisphosphonates require Authority for osteoporosis criteria. Dapsone (for dermatitis herpetiformis) is Authority Required. Pneumococcal vaccines are free under the NIP for medical risk groups.

Mental health: Adjustment to a strict lifelong dietary restriction carries psychological burden. The MHCP (items 2715/2717) is applicable for psychological support. An eating disorder differential should be considered in patients with excessive dietary restriction anxiety — refer for assessment if this is apparent.

Telehealth: appropriate for ongoing monitoring reviews, result review, and dietitian coordination once the 12-month existing-relationship requirement is met.

E. Special populations

Paediatric presentation. In children, coeliac disease may present with failure to thrive, short stature, delayed puberty, behavioural changes, or iron deficiency anaemia. Paediatric gastroenterology referral is appropriate. No-biopsy diagnosis is more established in paediatric practice, but should only be applied with appropriate serology thresholds and symptom criteria.

Pregnancy. Untreated or poorly controlled coeliac disease is associated with increased miscarriage risk, preterm birth, and low birthweight. Folate 5 mg per day (high-dose) pre-conception is recommended. Strict dietary adherence during pregnancy is essential; nutritional repletion — particularly iron, folate, and vitamin D — requires active monitoring.

Older adults at diagnosis. Late-diagnosed adults may have accumulated significant bone loss. DXA at diagnosis is particularly important. Bisphosphonate initiation should follow standard clinical criteria but coeliac disease itself lowers the threshold for intervention given cumulative malabsorption.

Refractory coeliac disease. Persistent symptoms and/or ongoing villous atrophy despite strict dietary adherence for ≥12 months (confirmed by dietitian review) is refractory coeliac. This requires specialist gastroenterology co-management and investigation for Type II refractory disease (a precursor to EATL). Dietary lapses are far more common than true refractory disease and should be explored first with a detailed dietitian assessment.

When to escalate

Refer to the emergency department for: coeliac crisis (severe diarrhoea, dehydration, electrolyte disturbance) or new severe symptoms in a known coeliac patient suggesting EATL (unexplained weight loss, severe abdominal pain, fever, lymphadenopathy).

Same-week gastroenterology referral for: new diagnosis with strongly positive serology awaiting biopsy, refractory disease, persistent positive serology on dietary adherence, severe nutritional deficiency requiring specialist input, or pregnancy with coeliac-related complications.

Routine referral: initial post-diagnosis gastroenterology review, ongoing annual review if complex, bone health management.

What this article is and is not

This is general health information drawn from Coeliac Australia, eTG, GESA, AMH, RACGP, and Healthy Bones Australia guidance. It is not personal medical advice and does not create a doctor–patient relationship. Specific diagnostic and treatment decisions are made with your own GP, gastroenterologist, and accredited dietitian.

AU consumer resources: Coeliac Australia, HealthDirect — Coeliac disease, Better Health Channel — Coeliac disease.

---

Sources cited

1. Coeliac Australia — Testing for coeliac disease
2. Therapeutic Guidelines (eTG) — Gastrointestinal: Coeliac disease
3. GESA — Coeliac disease resources
4. Australian Medicines Handbook
5. RACGP — Coeliac disease
6. Healthy Bones Australia — Osteoporosis
7. National Immunisation Program — Pneumococcal for medical risk groups
8. ESsCD 2025 European guideline on coeliac disease
9. HealthDirect — Coeliac disease
10. Better Health Channel — Coeliac disease